Cataluña allocates 9.5 million to Peris, its health innovation plan

Source: redaccionmedica.com The government has approved this Tuesday for 9.550.000 euros to attend the 2019 call for grants of the Strategic Plan for Research and Innovation in Health (Peris 2016-2020). This project is one of the axes of the Ministry of Health for planning, momentum and coordination and innovation for the coming years. The objective […]

New advances in the treatment of head and neck tumors

Source: immedicohospitalario.es Immunotherapy with pembrolizumab improves survival in patients with head and neck cancer that has recurred or metastasized according to the most recent results of the KEYNOTE-048 study presented at the Congress of the European Society of Medical Oncology, ESMO 2018 that is celebrated until on the 23rd in Munich. The current reference treatment […]

Gilead increases its commitment to research in Spain targeting HIV

Source: redaccionmedica.com The biopharmaceutical company Gilead Sciences continues its commitment to research in our country, this time, developing a project to achieve the cure of HIV. It will count with the collaboration of AELIX Therapeutics, a clinical phase biotechnology company specialized in the discovery and development of immunotherapies against the infection of this virus. Both […]

Breast cancer: the industry leads the research of 169 new drugs

Source: redaccionmedica.com Currently, the pharmaceutical industry has a total of 169 new drugs against breast cancer in the clinical research phase, a disease that encompasses the greatest efforts in R & D by companies. In recent years, 195 clinical trials have been registered in Spain, driven mostly by laboratories, focusing on this pathology of which […]

Success of the first trial of Opsumit (Actelion) in portopulmonary hypertension

Source: redaccionmedica.com Actelion Pharmaceuticals has announced the results of the first randomized controlled trial in portopulmonary hypertension (HTPP). This study has shown that Opsumit (macitentan) significantly improves pulmonary vascular resistance (PVR) compared with placebo. Presented as an oral communication at the recent meeting of the European Society of Pneumology (ERS) in Paris, the treatment of […]

Europe approves Verzenios, from Lilly, for the treatment of advanced breast cancer

Source: actasanitaria.com The European Commission has authorized the commercialization of Verzenios (abemaciclib), from the pharmaceutical company Lilly, as a treatment of locally advanced or metastatic breast cancer with positive hormone receptors (HR +) and receptor 2 of human negative epidermal growth factor (HER2-) , in combination with an aromatase inhibitor (AI) or fulvestrant as a […]

Genetic mutations also alter the nature of clinical trials

Source: immedicohospitalario.es New ways of researching and developing drugs, in their most advanced oncological aspects, urge health administrations, hospitals, patients and their organizations, Research Ethics Committees (CEIm), Contract Research Organizations (CRO) and national and transnational companies arbitrate systems that make available the most innovative therapies available to patients. Currently, the research for the development and […]

VHIO develops a precision immunotherapy for breast cancer

Source: redaccionmedica.com Researchers at the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona have achieved that immunotherapy attacks only the tumor cells of a type of breast cancer in patients who do not respond to other treatments, an action “at home” that solves one of The main challenges for this novel strategy in Oncology. The […]

Nobel Prize for Medicine 2018 for cancer immunotherapy

Source: IntraMed The American James Allison and the Japanese Tasuku Honjo have won the Nobel Prize for Medicine 2018. The jury of the Karolinska Institute in Stockholm has awarded the prize to these two scientists for “their discovery of cancer therapy by inhibiting negative immune regulation ” The findings of both scientists have been essential […]

EMA gives a positive opinion to Gilenya, from Novartis, for minors with multiple sclerosis

Source: actasanitaria.com The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of the drug Gilenya (fingolimod), from the pharmaceutical company Novartis, to treat children and adolescents from 10 to 17 years of age with referral forms recurrent multiple sclerosis. If approved, said pharmaceutical company indicates […]